PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 27346437-0 2017 Long-term effects of angiotensin II blockade with irbesartan on inflammatory markers in hemodialysis patients: A randomized double blind placebo controlled trial (SAFIR study). Irbesartan 50-60 angiotensinogen Homo sapiens 21-35 34620946-7 2021 Our previous work showed that irbesartan, an Ang II type 1 receptor blocker, reduced the number of C-C chemokine receptor 2-positive (CCR2+) monocytic cells in the inflamed pancreas. Irbesartan 30-40 angiotensinogen Homo sapiens 45-51 33222389-7 2021 Specifically, olmesartan blocks both angiotensin II (AngII) binding and mechanical activation of AT1Rs, whereas irbesartan prevents only AngII binding to AT1Rs. Irbesartan 112-122 angiotensinogen Homo sapiens 137-142 33708834-0 2021 Irbesartan inhibits metastasis by interrupting the adherence of tumor cell to endothelial cell induced by angiotensin II in hepatocellular carcinoma. Irbesartan 0-10 angiotensinogen Homo sapiens 106-120 33708834-3 2021 Methods: The effects of angiotensin II and irbesartan (an angiotensin II inhibitor) on HCC were explored with a xenograft model, microarray analysis and cell adhesion experiments. Irbesartan 43-53 angiotensinogen Homo sapiens 58-72 33708834-8 2021 Irbesartan inhibited HCC growth and metastasis in vivo and weakened the adhesion of HCC cells to endothelial cells, an effect that was enhanced by angiotensin II. Irbesartan 0-10 angiotensinogen Homo sapiens 147-161 33708834-10 2021 Angiotensin II upregulated VCAM-1 expression, and this upregulation was inhibited by irbesartan. Irbesartan 85-95 angiotensinogen Homo sapiens 0-14 33708834-12 2021 Irbesartan inhibited the expression of VCAM-1 by reducing p38/MAPK phosphorylation activated by angiotensin II in HCC cells. Irbesartan 0-10 angiotensinogen Homo sapiens 96-110 33708834-13 2021 Conclusions: Irbesartan attenuates metastasis by inhibiting angiotensin II-activated VCAM-1 via the p38/MAPK pathway in HCC. Irbesartan 13-23 angiotensinogen Homo sapiens 60-74 32983943-1 2020 Introduction: Irbesartan (IBS), an angiotensin II receptor (AT1 subtype) antagonist which blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selective binding to AT1 angiotensin II receptor. Irbesartan 14-24 angiotensinogen Homo sapiens 35-49 32983943-1 2020 Introduction: Irbesartan (IBS), an angiotensin II receptor (AT1 subtype) antagonist which blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selective binding to AT1 angiotensin II receptor. Irbesartan 14-24 angiotensinogen Homo sapiens 154-168 33461698-5 2021 Irbesartan exerts its action mainly via a selective blockade action on AT1 receptors and the consequent reduced pressor effect of angiotensin II. Irbesartan 0-10 angiotensinogen Homo sapiens 130-144 30865228-7 2019 In primary culture of human parathyroid cells, both aldosterone (P < 0.001) and angiotensin II (P = 0.002) markedly increased PTH secretion from baseline, by acting through mineralocorticoid receptor and angiotensin type 1 receptor, as these effects were abolished by canrenone and irbesartan, respectively. Irbesartan 282-292 angiotensinogen Homo sapiens 80-94 30405294-3 2018 Interventions: The study participants received either a placebo or irbesartan, (150 mg PO), an Ang II receptor antagonist, for seven days prior to stress testing. Irbesartan 67-77 angiotensinogen Homo sapiens 95-101 26030651-0 2015 Short and Long-Term Effects of the Angiotensin II Receptor Blocker Irbesartan on Intradialytic Central Hemodynamics: A Randomized Double-Blind Placebo-Controlled One-Year Intervention Trial (the SAFIR Study). Irbesartan 67-77 angiotensinogen Homo sapiens 35-49 27932705-5 2016 The effect of the ARB irbesartan on the expression of AGT in the nephrotic model was analyzed. Irbesartan 22-32 angiotensinogen Homo sapiens 54-57 27564102-6 2016 Treatment with irbesartan or AT1R-RNAi knockdown but not treatment with PD123319 significantly decreased the level of angiotensin II-induced ESCC cell proliferation. Irbesartan 15-25 angiotensinogen Homo sapiens 118-132 27564102-10 2016 In a xenograft model, local angiotensin II injection enhanced tumor growth, and this effect could be decreased by treatment with irbesartan or everolimus. Irbesartan 129-139 angiotensinogen Homo sapiens 28-42 26030651-2 2015 The present study evaluated the use of the angiotensin II receptor blocker (ARB) irbesartan. Irbesartan 81-91 angiotensinogen Homo sapiens 43-57 25551221-11 2014 Irbesartan treatment also suppressed induction of adipose angiotensinogen and proinflammatory cytokines in WAT and blood, and reversed changes in adiponectin expression. Irbesartan 0-10 angiotensinogen Homo sapiens 58-73 25423498-1 2015 AIM: The aim of this paper was to compare the efficacy of in vitro calycosin and irbesartan for the treatment of angiotensin II (AngII)-induced renin angiotensin system (RAS) disorder in human umbilical vein endothelial cells (HUVECs). Irbesartan 81-91 angiotensinogen Homo sapiens 113-127 25423498-1 2015 AIM: The aim of this paper was to compare the efficacy of in vitro calycosin and irbesartan for the treatment of angiotensin II (AngII)-induced renin angiotensin system (RAS) disorder in human umbilical vein endothelial cells (HUVECs). Irbesartan 81-91 angiotensinogen Homo sapiens 129-134 25423498-6 2015 Interestingly, Calycosin was able to inhibit the effect of AngII in a concentration dependent manner, and its effect at concentration of 35 mumol was equal to that of positive control Irbesartan (10mumol). Irbesartan 184-194 angiotensinogen Homo sapiens 59-64 21609598-5 2011 RESULTS: Exploring the affect of irbesartan on AngII through the Western blot analysis of CTGF and RhoA protein expression: the CTGF level was up-regulated by AngII (0.89 +- 0.05 vs control 0.48 +- 0.10, P < 0.01). Irbesartan 33-43 angiotensinogen Homo sapiens 47-52 22842919-7 2012 In addition, irbesartan and A779, which are inhibitors of AT1R and Mas, respectively, attenuated the effect of Ang II and Ang-(1-7). Irbesartan 13-23 angiotensinogen Homo sapiens 111-117 22426690-7 2012 ARBs, and in particular irbesartan, effectively inhibited the effects of Ang II on cell proliferation, cell cycle development and downstream AT1R signaling events, including the activation of the Ras-Raf-MAPK pathway and the transcription factors NF-kappaB and CREB. Irbesartan 24-34 angiotensinogen Homo sapiens 73-79 21384133-1 2012 The aim of this study was to assess the effect of the angiotensin II receptor blocker Irbesartan on protein damage by glycation, oxidation and nitration in patients with type 2 diabetes and microalbuminuria. Irbesartan 86-96 angiotensinogen Homo sapiens 54-68 21384133-10 2012 This is likely achieved by blocking angiotensin II signalling and related down-regulation of glyoxalase 1 and may contribute to health benefits of Irbesartan therapy. Irbesartan 147-157 angiotensinogen Homo sapiens 36-50 23743807-5 2013 Irbesartan decreased plasma angiotensinogen by approximately 25%, and no changes in plasma angiotensinogen were observed during the combination. Irbesartan 0-10 angiotensinogen Homo sapiens 28-43 23743807-7 2013 Both blockers reduced urinary angiotensinogen, significant for irbesartan only. Irbesartan 63-73 angiotensinogen Homo sapiens 30-45 22388234-5 2012 METHOD: In a post-hoc analysis of the Reduction of Endpoints in Non insulin dependent diabetes mellitus with the Angiotensin II Antagonist Losartan (RENAAL) and Irbesartan Diabetic Nephropathy (IDNT) trials we determined whether the short-term effect of losartan and of irbesartan on SUA is related with long-term cardiovascular outcome by means of Cox regression. Irbesartan 270-280 angiotensinogen Homo sapiens 113-127 21236267-4 2011 In this study, we examined whether and how irbesartan, an angiotensin II type 1 receptor blocker (ARB), inhibited the AGE-induced vascular cell adhesion molecule-1 (VCAM-1) gene expression in cultured human glomerular ECs. Irbesartan 43-53 angiotensinogen Homo sapiens 58-72 21236267-7 2011 Furthermore, irbesartan completely suppressed up-regulation of VCAM-1 mRNA levels in AGE plus angiotensin II-exposed glomerular ECs. Irbesartan 13-23 angiotensinogen Homo sapiens 94-108 21236267-9 2011 Irbesartan may play a protective role against diabetic nephropathy by blocking the deleterious effects of AGE-elicited angiotensin II and ROS. Irbesartan 0-10 angiotensinogen Homo sapiens 119-133 21609598-5 2011 RESULTS: Exploring the affect of irbesartan on AngII through the Western blot analysis of CTGF and RhoA protein expression: the CTGF level was up-regulated by AngII (0.89 +- 0.05 vs control 0.48 +- 0.10, P < 0.01). Irbesartan 33-43 angiotensinogen Homo sapiens 159-164 21609598-7 2011 After the use of AngII, the expression of RhoA protein was significantly enhanced (3.40 +- 0.46 vs control 1.77 +- 0.37, P < 0.01) and blunted by a pretreatment of irbesartan (2.27 +- 0.45, P < 0.05). Irbesartan 167-177 angiotensinogen Homo sapiens 17-22 21949635-2 2011 Irbesartan exerts its antihypertensive effect through an inhibitory effect on the pressure response to angiotensin II. Irbesartan 0-10 angiotensinogen Homo sapiens 103-117 23781414-1 2010 INTRODUCTION: Irbesartan, a diazaspiro angiotensin II blocker, is marketed in combination with Hydrochlorothiazide, which is a diuretic acting on distal convoluted tubule; for synergistic anti-hypertensive action. Irbesartan 14-24 angiotensinogen Homo sapiens 39-53 19795011-8 2009 In the IDNT study, angiotensin II blockade with irbesartan was found to lead to an absolute reduction of renal events by 7.4% as compared to standard treatment, and by 9.5% as compared to amlodipine. Irbesartan 48-58 angiotensinogen Homo sapiens 19-33 21949618-1 2010 Irbesartan, an angiotensin II type 1 receptor antagonist, is approved as monotherapy, or in combination with other drugs, for the treatment of hypertension in many countries worldwide. Irbesartan 0-10 angiotensinogen Homo sapiens 15-29 21949618-5 2010 Irbesartan has an inhibitory effect on the pressor response to angiotensin II and improves arterial stiffness, vascular endothelial dysfunction, and inflammation in hypertensive patients. Irbesartan 0-10 angiotensinogen Homo sapiens 63-77 20663195-12 2010 CONCLUSIONS: These findings suggest a novel mechanism in HG-induced endothelial damage via the mediation of the EndMT by angiotensin II, which was inhibited by Irbesartan. Irbesartan 160-170 angiotensinogen Homo sapiens 121-135 18993115-7 2008 Effects became significant at concentrations >1 nmol/L Ang II and were maximal at 1000 nmol/L (increase in twitch force to 157+/-14% and AECs from 0 to 80%) saralasin and irbesartan partially prevented the inotropic effect of 100 nmol/L Ang II (by 45+/-12% and 68+/-6%; p<0.05), and completely prevented the occurrence of AECs. Irbesartan 174-184 angiotensinogen Homo sapiens 58-64 18993115-7 2008 Effects became significant at concentrations >1 nmol/L Ang II and were maximal at 1000 nmol/L (increase in twitch force to 157+/-14% and AECs from 0 to 80%) saralasin and irbesartan partially prevented the inotropic effect of 100 nmol/L Ang II (by 45+/-12% and 68+/-6%; p<0.05), and completely prevented the occurrence of AECs. Irbesartan 174-184 angiotensinogen Homo sapiens 240-246 18633426-1 2008 Irbesartan, an angiotensin-II inhibitor, has been shown to be an effective antihypertensive agent in clinical trials. Irbesartan 0-10 angiotensinogen Homo sapiens 15-29 18687761-0 2008 Irbesartan attenuates Ang II-induced BMP-2 expression in human umbilical vein endothelial cells. Irbesartan 0-10 angiotensinogen Homo sapiens 22-28 18687761-3 2008 Here we show that Ang II treatment significantly increased BMP-2 expression, associated with NF-kappaB activation, which was suppressed by treatment with pyrrolidine dithiocarbamate (PDTC) or irbesartan. Irbesartan 192-202 angiotensinogen Homo sapiens 18-24 18687761-4 2008 Furthermore, the increased levels of MDA (malondialdehyde) in conditioned media and the decrease in activities of total superoxide dismutases (SOD) caused by Ang II were reversed by irbesartan or PDTC treatment. Irbesartan 182-192 angiotensinogen Homo sapiens 158-164 18227384-11 2008 Atrial tachycardia caused an upregulation of VCAM-1 expression, which was prevented by irbesartan, consistent with the observed increase in plasma levels of angiotensin II. Irbesartan 87-97 angiotensinogen Homo sapiens 157-171 18422814-11 2008 CONCLUSIONS: Combination treatment of propranolol plus irbesartan is well tolerated in cirrhotic patients when titrating the angiotensin II antagonist in a step-up manner, and it increases sodium excretion in patients with compensated or moderately decompensated cirrhosis. Irbesartan 55-65 angiotensinogen Homo sapiens 125-139 15939823-8 2005 Finally, secretion of OPG from human AAA explant was abrogated by treatment with the angiotensin II blocker irbesartan, with the reduction in secreted levels averaging 63.0+/-0.9 ng/mg tissue per 48-hour period. Irbesartan 108-118 angiotensinogen Homo sapiens 85-99 18666803-4 2008 The purpose of the CREATIVE-AF (Impact of Irbesartan on Oxidative Stress and C-Reactive Protein Levels in Patients with Persistent Atrial Fibrillation) trial is to prove the principle concept that blockade of angiotensin II type 1 receptors by irbesartan reduces levels of circulating adhesion molecules and oxidative stress parameters in patients with persistent AF by 25% compared with placebo. Irbesartan 42-52 angiotensinogen Homo sapiens 209-223 18666803-4 2008 The purpose of the CREATIVE-AF (Impact of Irbesartan on Oxidative Stress and C-Reactive Protein Levels in Patients with Persistent Atrial Fibrillation) trial is to prove the principle concept that blockade of angiotensin II type 1 receptors by irbesartan reduces levels of circulating adhesion molecules and oxidative stress parameters in patients with persistent AF by 25% compared with placebo. Irbesartan 244-254 angiotensinogen Homo sapiens 209-223 17762662-14 2007 The findings with irbesartan suggest a role for angiotensin II in the control of myocardial fibrosis and diastolic function in patients with hypertension with LVH. Irbesartan 18-28 angiotensinogen Homo sapiens 48-62 17444886-9 2007 CONCLUSIONS: The favourable effects by irbesartan on CCA IMT with an outward vascular remodelling suggest that angiotensin II mediates structural vascular changes, beyond the effects of blood pressure. Irbesartan 39-49 angiotensinogen Homo sapiens 111-125 17192509-5 2007 Plasma angiotensin levels significantly increased only after irbesartan treatment (Ang II: 35 +/- 4 vs 329 +/- 101 pg/mL [P = .02]; Ang-(1-7): 10 +/- 3 vs 35 +/- 6 pg/mL [P = .01]) compared to atorvastatin treatment (Ang II: 26 +/- 5 vs 31 +/- 4 pg/mL [P = ns]; Ang-(1-7): 9 +/- 2 vs 11 +/- 3 pg/mL [P = ns]). Irbesartan 61-71 angiotensinogen Homo sapiens 83-89 16794485-6 2006 Both carvedilol and the angiotensin II type 1 (AT1) receptor antagonist irbesartan inhibited this angiotensin II-induced potentiation. Irbesartan 72-82 angiotensinogen Homo sapiens 24-38 16321381-0 2005 Effects of losartan and irbesartan administration on brain angiotensinogen mRNA levels. Irbesartan 24-34 angiotensinogen Homo sapiens 59-74 15881846-13 2005 Irbesartan, an angiotensin II antagonist, reduced fibroblast growth. Irbesartan 0-10 angiotensinogen Homo sapiens 15-29 15662225-8 2005 These enhanced responses were likely due to an increased angiotensin receptor 1 (AT1) expression in cells from FH patients induced by AngII, and were prevented by pretreating cells with the selective AT1 antagonist irbesartan. Irbesartan 215-225 angiotensinogen Homo sapiens 134-139 15749161-4 2005 In this article, several angiotensin II AT(1) receptor antagonists (candesartan, E3174, eprosartan, irbesartan and losartan) and aldosterone receptor antagonists (canrenoic acid and spironolactone) that directly modulate the activity of the voltage-dependent K(+) channels are reviewed; the effects of these antagonists might be useful in the prevention and treatment of cardiac arrhythmias. Irbesartan 100-110 angiotensinogen Homo sapiens 25-39 15761243-9 2005 Exogenous Ang II increased net O2* accumulation by 2.7-fold (p < 0.01), which was normalized by losartan and irbesartan. Irbesartan 112-122 angiotensinogen Homo sapiens 10-16 15761243-5 2005 Ang II action was antagonized by employing 10(-4) M of Ang II receptor antagonists (losartan or irbesartan) or 10(-4) M of NADH/NADPH oxidase inhibitors [diphenyleneiodonium chloride (DPI) or apocynin]. Irbesartan 96-106 angiotensinogen Homo sapiens 0-6 15614026-6 2004 Two SNPs in two separate genes (the angiotensinogen T1198C polymorphism, corresponding to the M235T variant and the apolipoprotein B G10108A polymorphism) for those treated with irbesartan, and the adrenoreceptor alpha2A A1817G for those treated with atenolol, significantly predicted the change in LV mass. Irbesartan 178-188 angiotensinogen Homo sapiens 36-51 15167450-10 2004 In-vitro incubation of platelets with angiotensin II elicited a significant increase in O2 (P < 0.001) that was dose-dependently inhibited by irbesartan and diphenylene iodonium, an inhibitor of NADPH oxidase. Irbesartan 145-155 angiotensinogen Homo sapiens 38-52 14730203-6 2004 RESULTS: The ET-1 gene was induced with Ang II, which was inhibited with Ang II type 1 receptor antagonist (irbesartan). Irbesartan 108-118 angiotensinogen Homo sapiens 40-46 15109447-0 2004 Effect of irbesartan on angiotensin II-induced hypertrophy of human proximal tubular cells. Irbesartan 10-20 angiotensinogen Homo sapiens 24-38 15134586-7 2004 The AT1 receptor antagonist Irbesartan antagonized the actions of Ang II. Irbesartan 28-38 angiotensinogen Homo sapiens 66-72 14730203-6 2004 RESULTS: The ET-1 gene was induced with Ang II, which was inhibited with Ang II type 1 receptor antagonist (irbesartan). Irbesartan 108-118 angiotensinogen Homo sapiens 73-79 14730203-7 2004 Ang II-enhanced intracellular ROS levels were inhibited by irbesartan and several antioxidants, and antioxidants also suppressed Ang II-induced ET-1 gene expression. Irbesartan 59-69 angiotensinogen Homo sapiens 0-6 14730203-7 2004 Ang II-enhanced intracellular ROS levels were inhibited by irbesartan and several antioxidants, and antioxidants also suppressed Ang II-induced ET-1 gene expression. Irbesartan 59-69 angiotensinogen Homo sapiens 129-135 14639093-5 2003 Plasma renin activity and angiotensin II increased (P < 0.001) by irbesartan (0.9 +/- 0.7 to 3.4 +/- 4.2 ng/mL x h, and 3.0 +/- 1.6 to 13.0 +/- 17.7 pmol/L), but decreased (P < 0.01) by atenolol (1.0 +/- 0.6 to 0.7 +/- 0.6 ng/mL x h, and 3.4 +/- 1.6 to 3.2 +/- 2.2 pmol/L). Irbesartan 69-79 angiotensinogen Homo sapiens 26-40 14639093-7 2003 Changes in left ventricular mass by irbesartan related inversely to changes in plasma renin activity, angiotensin II, and aldosterone (all P < 0.05). Irbesartan 36-46 angiotensinogen Homo sapiens 102-116 15030294-1 2003 Irbesartan is a long-acting angiotensin II antagonist acting specifically at the level of the Type 1-receptor subtype (AT1-receptor). Irbesartan 0-10 angiotensinogen Homo sapiens 28-42 12969165-1 2003 BACKGROUND: The dihydropyridine calcium channel blocker amlodipine and the angiotensin II antagonist irbesartan effectively reduce blood pressure in hypertensive children. Irbesartan 101-111 angiotensinogen Homo sapiens 75-89 12827025-3 2003 In the presence of indomethacin (10 microM) and Nomega-nitro-L-arginine (100 microM), irbesartan, valsartan, and EXP3174 induced a rightward shift of U46619- and angiotensin II-induced contraction. Irbesartan 86-96 angiotensinogen Homo sapiens 162-176 13678427-7 2003 CONCLUSIONS: The ALAP genotype seems to determine the degree of regression of left ventricular hypertrophy during antihypertensive treatment with the angiotensin II type I receptor antagonist irbesartan in patients with essential hypertension and left ventricular hypertrophy. Irbesartan 192-202 angiotensinogen Homo sapiens 150-164 15030294-6 2003 Irbesartan may have antiatherosclerotic properties beyond those expected from blood pressure lowering per se: this AT1-blocker decreases the vascular oxidative stress and prevents the procoagulant as well as the pro-inflammatory effects of angiotensin II. Irbesartan 0-10 angiotensinogen Homo sapiens 240-254 11910301-4 2002 Patients with the angiotensinogen 174 TM genotype treated with irbesartan responded with the greatest reduction in LVM (-23 +/- 31SD g/m2 for TM and +0.5 +/- 18 g/m2 for TT, P = 0.005), independent of blood pressure reduction. Irbesartan 63-73 angiotensinogen Homo sapiens 18-33 12452749-5 2002 DISCUSSION: An objective causality assessment indicates that it is probable that pancreatitis was caused by the angiotensin II receptor antagonist irbesartan (and the same is probably true for losartan). Irbesartan 147-157 angiotensinogen Homo sapiens 112-126 11904530-0 2002 Pharmacodynamic studies on the angiotensin II type 1 antagonists irbesartan and candesartan based on angiotensin II dose response in humans. Irbesartan 65-75 angiotensinogen Homo sapiens 31-45 11904530-4 2002 Both drugs exerted similar substantial (> 30-fold) and long-lasting (> 2-fold 47 h after dosing) rightward shifts of the angiotensin II dose effect declining with half-lives of 15 h irbesartan and 12 h candesartan, respectively. Irbesartan 188-198 angiotensinogen Homo sapiens 127-141 12460701-0 2002 Effectiveness and safety of the angiotensin II antagonist irbesartan in children with chronic kidney diseases. Irbesartan 58-68 angiotensinogen Homo sapiens 32-46 12460701-1 2002 BACKGROUND: Studies in adults with chronic kidney diseases demonstrate that the orally available angiotensin II antagonist irbesartan reduces arterial pressure and pathological proteinuria, mostly with an excellent tolerability profile. Irbesartan 123-133 angiotensinogen Homo sapiens 97-111 12851994-1 2002 Irbesartan, an angiotensin II receptor antagonist (AIIRA), is an antihypertensive agent that inhibits the activity of angiotensin II by selectively binding to angiotensin II type 1 (AT1) receptors. Irbesartan 0-10 angiotensinogen Homo sapiens 15-29 12851994-1 2002 Irbesartan, an angiotensin II receptor antagonist (AIIRA), is an antihypertensive agent that inhibits the activity of angiotensin II by selectively binding to angiotensin II type 1 (AT1) receptors. Irbesartan 0-10 angiotensinogen Homo sapiens 118-132 12851994-1 2002 Irbesartan, an angiotensin II receptor antagonist (AIIRA), is an antihypertensive agent that inhibits the activity of angiotensin II by selectively binding to angiotensin II type 1 (AT1) receptors. Irbesartan 0-10 angiotensinogen Homo sapiens 118-132 12172412-0 2002 Cholestatic hepatitis related to use of irbesartan: a case report and a literature review of angiotensin II antagonist-associated hepatotoxicity. Irbesartan 40-50 angiotensinogen Homo sapiens 93-107 12172412-1 2002 We report a patient who developed cholestatic hepatitis shortly after starting therapy with irbesartan, one of the new, recently marketed angiotensin II antagonists. Irbesartan 92-102 angiotensinogen Homo sapiens 138-152 11910301-5 2002 Both the angiotensinogen 235 T-allele (P = 0.02) and the AT1-receptor 1166 AC genotype responded with the greatest reduction in LVM when treated with irbesartan (-0.1 +/- 19 g/m2 for AA and -18 +/- 30 g/m2 for AC, P = 0.02), independent of blood pressure reduction. Irbesartan 150-160 angiotensinogen Homo sapiens 9-24 11998539-1 2002 PURPOSE: A Prescription Event Monitoring (PEM) study was carried out by the Drug Safety Research Unit (DSRU) to monitor the safety of irbesartan, an angiotensin II antagonist, immediately after launch in the United Kingdom in September 1997. Irbesartan 134-144 angiotensinogen Homo sapiens 149-163 12378864-8 2002 All today available angiotensin II receptor antagonists--losartan, valsartan, irbesartan, candesartan, eprosartan, and telmisartan--equally lower both systolic and diastolic pressure. Irbesartan 78-88 angiotensinogen Homo sapiens 20-34 11855558-0 2002 Efficacy of irbesartan, a receptor selective antagonist of angiotensin II, in reducing portal hypertension. Irbesartan 12-22 angiotensinogen Homo sapiens 59-73 11901904-3 2002 Angiotensin II antagonists (irbesartan and losartan) are able to reduce the rate of progression of diabetic nephropathy in hypertensive patients with type 2 diabetes. Irbesartan 28-38 angiotensinogen Homo sapiens 0-14 11963637-5 2002 AT1 receptor blockers (losartan, candesartan, irbesartan, valsartan) are available drugs in the angiotensin-II-antagonist class. Irbesartan 46-56 angiotensinogen Homo sapiens 96-110 11487548-0 2001 Hemodynamic effects of the angiotensin II receptor antagonist irbesartan in patients with cirrhosis and portal hypertension. Irbesartan 62-72 angiotensinogen Homo sapiens 27-41 11549097-9 2001 After dosing with irbesartan, mean increases in angiotensin II and PRA concentrations were higher in patients with heart failure than in the matched controls, but there was more interpatient variability in the patients with heart failure. Irbesartan 18-28 angiotensinogen Homo sapiens 48-62 12184030-2 2002 Irbesartan inhibits the action of angiotensin II, which acts through the binding to the AT1 receptor. Irbesartan 0-10 angiotensinogen Homo sapiens 34-48 11487548-2 2001 This randomized, placebo-controlled, double-blind study aimed to assess the effect of the angiotensin II receptor antagonist irbesartan on portal and systemic hemodynamics and renal function in patients with cirrhosis. Irbesartan 125-135 angiotensinogen Homo sapiens 90-104 11487548-9 2001 CONCLUSIONS: The angiotensin II receptor antagonist irbesartan is not advisable in patients with advanced cirrhosis and high plasma renin because it may induce arterial hypotension and only moderately reduces portal pressure. Irbesartan 52-62 angiotensinogen Homo sapiens 17-31 11465912-4 2001 Two independent studies have been conducted in which irbesartan exhibited a more pronounced and longer-lasting antagonism to the effects of exogenous Ang II than losartan and valsartan. Irbesartan 53-63 angiotensinogen Homo sapiens 150-156 11300658-2 2001 The purpose of this study was to assess the inhibitory effect of irbesartan on the pressor action of exogenous angiotensin II in healthy subjects, to evaluate the dose dependency and duration of this inhibition, and to determine the effect of irbesartan on plasma components of the renin-angiotensin system. Irbesartan 65-75 angiotensinogen Homo sapiens 111-125 11300658-6 2001 The inhibitory effect of irbesartan on the pressor response to angiotensin II was observed within 1 h after dosing, peaked between 2 and 4 h, and lasted more than 24 h for doses of 25 mg and more. Irbesartan 25-35 angiotensinogen Homo sapiens 63-77 11300658-8 2001 Two and 24 h after administration of irbesartan, 300 mg, the response of arterial blood pressure (systolic and diastolic) to a given dose of angiotensin II was reduced by approximately 100% and 60%, respectively. Irbesartan 37-47 angiotensinogen Homo sapiens 141-155 11300658-9 2001 Plasma concentrations of angiotensin II and active renin increased markedly after irbesartan administration, whereas plasma concentrations of aldosterone decreased. Irbesartan 82-92 angiotensinogen Homo sapiens 25-39 11300658-0 2001 Inhibition of the acute effects of angiotensin II by the receptor antagonist irbesartan in normotensive men. Irbesartan 77-87 angiotensinogen Homo sapiens 35-49 28095233-10 2001 Losartan and irbesartan caused a significant, dose-dependent rightward shift of the Ang II contraction-response curve in human subcutaneous arteries. Irbesartan 13-23 angiotensinogen Homo sapiens 84-90 28095239-8 2001 This enhanced contractile response to Ang II was not inhibited by the angiotensin II type 2 (AT2-receptor antagonist PD 123319 (0.1 microM), but was blocked in an insurmountable way by the angiotensin II type 1 (AT1)-receptor antagonist candesartan (1 nM) and in a surmountable manner by losartan (0.1 microM) and irbesartan (0.1 microM). Irbesartan 314-324 angiotensinogen Homo sapiens 38-44 11465912-6 2001 Recently, we have compared the Ang II antagonistic properties of irbesartan 150 mg/day and candesartan 8 mg/day. Irbesartan 65-75 angiotensinogen Homo sapiens 31-37 11465912-9 2001 Furthermore, plasma renin activity during periods with high antagonistic activity was significantly higher, and aldosterone levels following Ang II stimulation were blunted to a greater extent, following administration of irbesartan. Irbesartan 222-232 angiotensinogen Homo sapiens 141-147 11206708-3 2000 It was inhibited by other AT1 receptor antagonists with the same potency order as previously described for the binding of [3H]-angiotensin II and [3H]-candesartan to human AT1 receptors (i.e. candesartan > or = EXP3174 > valsartan = irbesartan = angiotensin II > losartan). Irbesartan 239-249 angiotensinogen Homo sapiens 127-141 11303957-9 2000 EXP3174, and irbesartan, coincubation experiments reveal that LY301875 and LY303336 interact with the AT1 receptor in a manner that is competitive with angiotensin II. Irbesartan 13-23 angiotensinogen Homo sapiens 152-166 15645839-1 2000 Irbesartan (Aprovel) belongs into the new group drugs for the cardiovascular system which exert an antagonistic effect at the level of angiotensin II, but experimental pilot studies as well as clinical studies draw also attention to the possible therapeutic potential of AT1 receptor blockers in the treatment of chronic heart failure. Irbesartan 0-10 angiotensinogen Homo sapiens 135-149 11053475-9 2000 Premedication with irbesartan almost completely blocked the vasoconstrictive effect of Ang II on renal vasculature. Irbesartan 19-29 angiotensinogen Homo sapiens 87-93 10968237-0 2000 Preliminary experience with the angiotensin II receptor antagonist irbesartan in chronic kidney disease. Irbesartan 67-77 angiotensinogen Homo sapiens 32-46 10968237-5 2000 A total of 20 children (aged 4 to 17 years) with chronic kidney disease received the angiotensin II antagonist irbesartan given once daily. Irbesartan 111-121 angiotensinogen Homo sapiens 85-99 10968237-10 2000 CONCLUSION: In children with chronic kidney disease the effects of the angiotensin II antagonist irbesartan on arterial pressure and proteinuria mimic those observed with the converting enzyme inhibitors. Irbesartan 97-107 angiotensinogen Homo sapiens 71-85 10852648-1 2000 Irbesartan interrupts the renin-angiotensin system via selective blockade of the angiotensin II subtype 1 receptor; the latter being responsible for the pressor related effects of angiotensin II. Irbesartan 0-10 angiotensinogen Homo sapiens 81-95 10852648-1 2000 Irbesartan interrupts the renin-angiotensin system via selective blockade of the angiotensin II subtype 1 receptor; the latter being responsible for the pressor related effects of angiotensin II. Irbesartan 0-10 angiotensinogen Homo sapiens 180-194 10822210-7 2000 Irbesartan is well absorbed, does not require biotransformation to an active metabolite to exert its antihypertensive activity, offers a large volume of distribution, has a half-life that is sufficient to allow once-daily dosing, is associated with a strong and consistent dose-response and has been demonstrated to provide a level of angiotensin II antagonism that is statistically superior to that offered by some other ARBs. Irbesartan 0-10 angiotensinogen Homo sapiens 335-349 10921256-3 2000 Vasoconstrictor factors were found to have an important part in vascular control in realization of efficacy of irbesartan, an antagonist of receptors to angiotensin II, in CHF patients. Irbesartan 111-121 angiotensinogen Homo sapiens 153-167 10684525-3 1999 Irbesartan-treated patients had significantly greater 24-hour area under the curve values for mean change from baseline in AII and PRA versus placebo-treated patients on day B15 (AII [pg mZ h/mL]: 261 +/- 515 vs 12 +/- 51; PRA [(ng/mL/h); h]:74 +/-162 vs -2 +/-14; P values >.05). Irbesartan 0-10 angiotensinogen Homo sapiens 123-126 10720881-4 2000 With irbesartan, mean blood pressure decreased significantly and proportionally to the baseline levels of active renin, and angiotensin I and II. Irbesartan 5-15 angiotensinogen Homo sapiens 124-144 10193713-3 1999 Irbesartan is an orally active antagonist of the angiotensin II AT1 receptor subtype with potential efficacy in heart failure. Irbesartan 0-10 angiotensinogen Homo sapiens 49-63 10541298-3 1999 PRA and renal vascular responses (inulin and para-aminohippurate clearance) to graded doses of an angiotensin II (AngII) antagonist, irbesartan, were assessed in eight healthy volunteers and 12 patients with type 2 diabetes mellitus and nephropathy on a 10 mmol Na intake, to activate the renin system. Irbesartan 133-143 angiotensinogen Homo sapiens 98-112 10541298-3 1999 PRA and renal vascular responses (inulin and para-aminohippurate clearance) to graded doses of an angiotensin II (AngII) antagonist, irbesartan, were assessed in eight healthy volunteers and 12 patients with type 2 diabetes mellitus and nephropathy on a 10 mmol Na intake, to activate the renin system. Irbesartan 133-143 angiotensinogen Homo sapiens 114-119 10546920-0 1999 Time course and extent of angiotensin II antagonism after irbesartan, losartan, and valsartan in humans assessed by angiotensin II dose response and radioligand receptor assay. Irbesartan 58-68 angiotensinogen Homo sapiens 26-40 10684525-3 1999 Irbesartan-treated patients had significantly greater 24-hour area under the curve values for mean change from baseline in AII and PRA versus placebo-treated patients on day B15 (AII [pg mZ h/mL]: 261 +/- 515 vs 12 +/- 51; PRA [(ng/mL/h); h]:74 +/-162 vs -2 +/-14; P values >.05). Irbesartan 0-10 angiotensinogen Homo sapiens 179-182 10684525-8 1999 CONCLUSIONS: Irbesartan increases plasma AII and PRA and lowers BP consistent with AT(1) receptor blockade, without clinically important effects on renal function. Irbesartan 13-23 angiotensinogen Homo sapiens 41-44 9607385-1 1998 Two multicenter, double-blind, placebo-controlled, parallel group studies were conducted to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of the angiotensin II receptor (AT1 subtype) antagonist irbesartan. Irbesartan 218-228 angiotensinogen Homo sapiens 169-183 10221067-3 1999 Irbesartan is a novel AT1 subtype angiotensin II receptor antagonist. Irbesartan 0-10 angiotensinogen Homo sapiens 34-48 8149971-0 1994 Effect of SR 47436, a novel angiotensin II AT1 receptor antagonist, on human vascular smooth muscle cells in vitro. Irbesartan 10-18 angiotensinogen Homo sapiens 28-42 9549663-1 1998 The safety, pharmacokinetics, and pharmacodynamics of single and multiple doses of the angiotensin II (AII) AT1 blocker irbesartan were assessed in healthy subjects. Irbesartan 120-130 angiotensinogen Homo sapiens 87-101 9549663-1 1998 The safety, pharmacokinetics, and pharmacodynamics of single and multiple doses of the angiotensin II (AII) AT1 blocker irbesartan were assessed in healthy subjects. Irbesartan 120-130 angiotensinogen Homo sapiens 103-106 9549663-8 1998 Irbesartan produced dose-dependent increases in plasma renin activity and AII levels. Irbesartan 0-10 angiotensinogen Homo sapiens 74-77 9475275-5 1998 Irbesartan administration was followed by an increase in active renin and plasma angiotensin II concentrations and renal plasma flow without change of systemic blood pressure, glomerular filtration rate, or plasma aldosterone concentration. Irbesartan 0-10 angiotensinogen Homo sapiens 81-95 9475275-9 1998 Pretreatment with irbesartan prevented all these effects of angiotensin II. Irbesartan 18-28 angiotensinogen Homo sapiens 60-74 9421695-2 1997 Irbesartan inhibits the activity of angiotensin II (AII) via specific, selective noncompetitive antagonism of the AII receptor subtype 1 (AT1) which mediates most of the known physiological activities of AII. Irbesartan 0-10 angiotensinogen Homo sapiens 36-50 9421695-2 1997 Irbesartan inhibits the activity of angiotensin II (AII) via specific, selective noncompetitive antagonism of the AII receptor subtype 1 (AT1) which mediates most of the known physiological activities of AII. Irbesartan 0-10 angiotensinogen Homo sapiens 52-55 9421695-2 1997 Irbesartan inhibits the activity of angiotensin II (AII) via specific, selective noncompetitive antagonism of the AII receptor subtype 1 (AT1) which mediates most of the known physiological activities of AII. Irbesartan 0-10 angiotensinogen Homo sapiens 114-117 9532514-6 1997 Irbesartan is a new angiotensin II receptor antagonist that provides specific and insurmountable antagonism of the AT1 receptor subtype, demonstrating a greater than 8500-fold specificity for the AT1 receptor, the subtype which mediates all the known actions of angiotensin, compared to the AT2 receptor. Irbesartan 0-10 angiotensinogen Homo sapiens 20-34 9532515-8 1997 The Collaborative Study pilot trial has already shown that the angiotensin II receptor antagonist irbesartan is significantly more effective than the calcium antagonist amlodipine on creatinine clearance in hypertensive NIDDM patients. Irbesartan 98-108 angiotensinogen Homo sapiens 63-77 9532515-10 1997 Other trials have indicated that the response to blocking angiotensin II receptors with irbesartan in patients with NIDDM is substantially larger than it is in healthy humans. Irbesartan 88-98 angiotensinogen Homo sapiens 58-72 9532516-0 1997 Human pharmacokinetic/pharmacodynamic profile of irbesartan: a new potent angiotensin II receptor antagonist. Irbesartan 49-59 angiotensinogen Homo sapiens 74-88 9532516-4 1997 Irbesartan is a new, unique angiotensin II receptor antagonist with favorable pharmacokinetic/pharmacodynamic properties that are close to ideal for an antihypertensive agent. Irbesartan 0-10 angiotensinogen Homo sapiens 28-42 9449566-1 1997 A selective, accurate, precise and reproducible high-performance liquid chromatographic assay was developed for the quantitation of irbesartan, an angiotensin II antagonist, in human plasma and urine samples. Irbesartan 132-142 angiotensinogen Homo sapiens 147-161 8797143-0 1996 Dose-ranging study of the angiotensin II receptor antagonist irbesartan (SR 47436/BMS-186295) on blood pressure and neurohormonal effects in salt-deplete men. Irbesartan 61-71 angiotensinogen Homo sapiens 26-40 8797143-1 1996 We characterised the blood pressure (BP) and hormonal responses to the oral angiotensin II (Ang II) receptor antagonist irbesartan (SR47436/BMS-186295) or placebo in normal men with an activated renin-angiotensin system (RAS) during salt depletion. Irbesartan 120-130 angiotensinogen Homo sapiens 76-90 8797143-1 1996 We characterised the blood pressure (BP) and hormonal responses to the oral angiotensin II (Ang II) receptor antagonist irbesartan (SR47436/BMS-186295) or placebo in normal men with an activated renin-angiotensin system (RAS) during salt depletion. Irbesartan 120-130 angiotensinogen Homo sapiens 92-98 8797143-10 1996 There was a dose-related reactive increase in PRA (to 35 ng/ml/h) and Ang II (to 450 pg/ml) with irbesartan. Irbesartan 97-107 angiotensinogen Homo sapiens 70-76 7611241-8 1995 A direct proximal tubular natriuretic effect of the angiotensin II antagonist could be demonstrated only with irbesartan. Irbesartan 110-120 angiotensinogen Homo sapiens 52-66 9438777-6 1997 The ability of RAS blockade using irbesartan, an AT1 angiotensin II receptor antagonist, to slow the progression in renal failure has been compared with that of the calcium channel blocker amlodipine and placebo in a pilot study. Irbesartan 34-44 angiotensinogen Homo sapiens 53-67 8149971-6 1994 In these same cells, SR 47436 potently inhibited the angiotensin II-induced [Ca2+]i increase (IC50 = 0.53 +/- 0.13 vs. 7.4 +/- 1.3 nM for DuP 753). Irbesartan 21-29 angiotensinogen Homo sapiens 53-67